CANC vs. XBI
Compare and contrast key facts about Tema Oncology ETF (CANC) and SPDR S&P Biotech ETF (XBI).
CANC and XBI are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. CANC is an actively managed fund by Tema. It was launched on Aug 14, 2023. XBI is a passively managed fund by State Street that tracks the performance of the S&P Biotechnology Select Industry Index. It was launched on Feb 6, 2006.
Performance
CANC vs. XBI - Performance Comparison
Loading graphics...
CANC vs. XBI - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
CANC Tema Oncology ETF | 5.69% | 42.92% | -5.37% | 510.51% | -85.34% | -51.82% |
XBI SPDR S&P Biotech ETF | 4.76% | 35.89% | 1.01% | 7.60% | -25.87% | -10.94% |
Returns By Period
In the year-to-date period, CANC achieves a 5.69% return, which is significantly higher than XBI's 4.76% return.
CANC
- 1D
- 4.66%
- 1M
- -2.88%
- YTD
- 5.69%
- 6M
- 27.93%
- 1Y
- 52.46%
- 3Y*
- 140.00%
- 5Y*
- —
- 10Y*
- —
XBI
- 1D
- 7.53%
- 1M
- 0.28%
- YTD
- 4.76%
- 6M
- 27.90%
- 1Y
- 58.08%
- 3Y*
- 19.00%
- 5Y*
- -1.29%
- 10Y*
- 9.32%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
CANC vs. XBI - Expense Ratio Comparison
CANC has a 0.75% expense ratio, which is higher than XBI's 0.35% expense ratio.
Return for Risk
CANC vs. XBI — Risk / Return Rank
CANC
XBI
CANC vs. XBI - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Tema Oncology ETF (CANC) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| CANC | XBI | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.94 | 2.02 | -0.08 |
Sortino ratioReturn per unit of downside risk | 2.59 | 2.70 | -0.11 |
Omega ratioGain probability vs. loss probability | 1.32 | 1.34 | -0.02 |
Calmar ratioReturn relative to maximum drawdown | 3.86 | 3.72 | +0.13 |
Martin ratioReturn relative to average drawdown | 13.76 | 13.98 | -0.22 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| CANC | XBI | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.94 | 2.02 | -0.08 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | -0.04 | — |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.29 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.04 | 0.36 | -0.39 |
Correlation
The correlation between CANC and XBI is 0.53, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Dividends
CANC vs. XBI - Dividend Comparison
CANC's dividend yield for the trailing twelve months is around 0.05%, less than XBI's 0.34% yield.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CANC Tema Oncology ETF | 0.05% | 0.06% | 3.00% | 0.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
XBI SPDR S&P Biotech ETF | 0.34% | 0.37% | 0.15% | 0.02% | 0.00% | 0.04% | 0.20% | 0.00% | 0.28% | 0.24% | 0.26% | 0.61% |
Drawdowns
CANC vs. XBI - Drawdown Comparison
The maximum CANC drawdown since its inception was -97.53%, which is greater than XBI's maximum drawdown of -63.89%. Use the drawdown chart below to compare losses from any high point for CANC and XBI.
Loading graphics...
Drawdown Indicators
| CANC | XBI | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.53% | -63.89% | -33.64% |
Max Drawdown (1Y)Largest decline over 1 year | -12.40% | -13.39% | +0.99% |
Max Drawdown (5Y)Largest decline over 5 years | — | -55.04% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -63.89% | — |
Current DrawdownCurrent decline from peak | -56.19% | -26.17% | -30.02% |
Average DrawdownAverage peak-to-trough decline | -73.91% | -20.91% | -53.00% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.61% | 3.71% | -0.10% |
Volatility
CANC vs. XBI - Volatility Comparison
The current volatility for Tema Oncology ETF (CANC) is 8.36%, while SPDR S&P Biotech ETF (XBI) has a volatility of 11.60%. This indicates that CANC experiences smaller price fluctuations and is considered to be less risky than XBI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| CANC | XBI | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.36% | 11.60% | -3.24% |
Volatility (6M)Calculated over the trailing 6-month period | 16.34% | 19.25% | -2.91% |
Volatility (1Y)Calculated over the trailing 1-year period | 27.24% | 29.24% | -2.00% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 285.66% | 32.23% | +253.43% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 285.66% | 32.15% | +253.51% |